Interesting point
The main issue is percutaneous administration vs the more complex way that Sirtex administers it - so it can be a commercial threat to Sirtex. Also the OSL patent allows for administration of the same radioisotope as Sirtex uses... as long as it has a bit of P32 thrown in (I havent looked at the patent for a while but that is my recollection as I asked the question to someone who used to work at OSL).
I suspect Sirtex wouldnt be interested but another pharmaceutical company or similar might.
However currently OSL doesnt have a lot of runs on the board and are still quoting a study from almost 10 years ago.
Remember Clinical Cell Culture and why that fell over ?
Interesting point The main issue is percutaneous administration...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $32.61K | 2.718M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 3184549 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 2495137 | 4 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |